Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

JS Berek, M Renz, S Kehoe, L Kumar… - … of Gynecology & …, 2021 - Wiley Online Library
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

[HTML][HTML] Mechanisms of cancer metastasis

M Castaneda, P den Hollander, NA Kuburich… - Seminars in cancer …, 2022 - Elsevier
Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

[HTML][HTML] Randomized trial of cytoreductive surgery for relapsed ovarian cancer

P Harter, J Sehouli, I Vergote, G Ferron… - … England Journal of …, 2021 - Mass Medical Soc
Background Treatment for patients with recurrent ovarian cancer has been mainly based on
systemic therapy. The role of secondary cytoreductive surgery is unclear. Methods We …

[HTML][HTML] Tumor angiogenesis: causes, consequences, challenges and opportunities

R Lugano, M Ramachandran, A Dimberg - Cellular and Molecular Life …, 2020 - Springer
Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …

Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG …

KN Moore, M Bookman, J Sehouli, A Miller… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To evaluate the addition of the humanized monoclonal antiprogrammed death
ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and …

[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer

I Ray-Coquard, P Pautier, S Pignata… - … England Journal of …, 2019 - Mass Medical Soc
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …

Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology

DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

Epithelial ovarian cancer: evolution of management in the era of precision medicine

S Lheureux, M Braunstein… - CA: a cancer journal for …, 2019 - Wiley Online Library
Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …

N Colombo, C Sessa, A du Bois, J Ledermann… - Annals of oncology, 2019 - Elsevier
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …

Epithelial ovarian cancer

S Lheureux, C Gourley, I Vergote, AM Oza - The Lancet, 2019 - thelancet.com
Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …